Island Pharmaceuticals (ASX:ILA) has taken a step forward in the development of its antiviral candidate galidesivir, securing a strategic partnership with the Texas Biomedical Research Institute, one of the world’s most advanced infectious disease centres and a critical player in high-containment pathogen research.
Island Pharmaceuticals secures key partnership with Texas Biomed
December 17, 2025 Australian Biotech
Latest Video
New Stories
-
BMS therapy secures Australian approval for psoriatic arthritis
September 3, 2026 - -
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 - -
Gilead returns to Medicines Australia as industry prepares to make the case for innovation
September 3, 2026 - - Latest News -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026 - -
ENA Respiratory secures funding to test antiviral nasal spray in people with asthma
September 2, 2026 - -
OncoSil pursues a reimbursement pathway as it prepares for US rollout
September 2, 2026 - - Australian Biotech -
Vitrafy takes its cryopreservation technology into the US cell therapy market
September 2, 2026 - - Australian Biotech
